Lonza: Combining Automation and Defined Culture Conditions to Enable Rapid Manufacturing of Robust CAR-T Cell Products
Friday, May 31, 2024 12:45 PM - 01:15 PM
Room 212-214
Corporate Session
Speaker
CAR-T cell therapies have revolutionized the oncology landscape, leading to unprecedented successes in the clinic. Despite the remarkable progress and the vast growth in the number of CAR-T cell programs transitioning into the clinic, the complex manufacturing process associated with these therapies presents challenges that impact patient accessibility to these potentially curative treatments. In recent years, the field has begun to explore shorter CAR-T cell manufacturing approaches that enable generation of products that are robust, possess stronger stem-like properties, and exhibit greater persistence when challenged in vitro and in vivo. In the clinic, first in-human trials of rapid-CAR-T cells support these observations, reporting notable anti-tumor responses from dose-level administrations remarkably lower than those used for products manufactured under longer-term protocols. At Lonza Personalized Medicine, we have generated Rapid Manufacturing processes that consolidate into an automated workflow the critical steps required for transforming T cells into potent CAR-T cell therapies in just 72 hours. Operating within the Lonza Cocoon® Platform, our rapid T cell manufacturing solutions enable automated activation and robust transduction in serum-containing and serum-free conditions to support flexible and streamlined processes.
- Tamara Laskowski, PhD, Global Head, Clinical & Process Development, Lonza Personalized Medicine
CAR-T cell therapies have revolutionized the oncology landscape, leading to unprecedented successes in the clinic. Despite the remarkable progress and the vast growth in the number of CAR-T cell programs transitioning into the clinic, the complex manufacturing process associated with these therapies presents challenges that impact patient accessibility to these potentially curative treatments. In recent years, the field has begun to explore shorter CAR-T cell manufacturing approaches that enable generation of products that are robust, possess stronger stem-like properties, and exhibit greater persistence when challenged in vitro and in vivo. In the clinic, first in-human trials of rapid-CAR-T cells support these observations, reporting notable anti-tumor responses from dose-level administrations remarkably lower than those used for products manufactured under longer-term protocols. At Lonza Personalized Medicine, we have generated Rapid Manufacturing processes that consolidate into an automated workflow the critical steps required for transforming T cells into potent CAR-T cell therapies in just 72 hours. Operating within the Lonza Cocoon® Platform, our rapid T cell manufacturing solutions enable automated activation and robust transduction in serum-containing and serum-free conditions to support flexible and streamlined processes.
SPONSORED BY:
